Medical Licensing (MD/DO) · Independent exam preparation
日本専門医機構認定放射線治療専門医認定試験: Selective Preparation Guide Study Guide
Practise radiotherapy selection, target definition, fractionation, toxicity recognition and safety decisions for Japan’s physician radiation therapy specialist certification examination.
By CertMedbry · Updated 18 October 2026
Practise choosing radiotherapy strategies, interpreting treatment plans, calculating radiobiological effects and recognizing treatment toxicity and preventable safety failures. This selective, independent guide develops 60 concepts for the Japanese Medical Specialty Board physician specialist examination in radiation therapy. The official examination outline and its governing March 2025 revised curriculum define the full scope; these selected topics do not replace them. Numerical domain weights are not published in the public notice.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certifying body does this guide address?
The selected pathway is the third 日本専門医機構認定放射線治療専門医認定試験. JASTRO and JRS issued the examination announcement, with the secretariat at JASTRO. Specialist certification requires Japanese Medical Specialty Board approval, and the Board issues certificates.
What examination components, dates and delivery arrangements are verified?
The 2026 notice specified a written examination on August 21 and an oral examination on August 22 at Kobe Portopia Hotel. The August 27 results announcement confirms that the examinations occurred there on those dates. Computer delivery, remote delivery and adaptive testing are not established by these sources.
How many questions are there, and how long does testing take?
The public notice does not establish question count, a scored/pretest split or component durations. It also does not specify written item styles, oral station structure or a passing score. The 20 four-option questions here are independent learning drills; their format and results do not establish the official examination format or predict passing.
Which curriculum version and domains govern the 2026 examination?
The notice dated April 6, 2026 states that questions follow the revised March 2025 curriculum, posted to the JRS member page on March 26, 2025. Its public outline lists radiation oncology and radiation therapy; radiation basic medicine and radiation safety management; and other subjects. This establishes applicability to the 2026 examination, not a separately verified curriculum implementation date.
How does this selective guide distribute study material across the outline?
No numerical domain weights are stated in the public notice, and constituent topics under Other are unspecified. This guide uses an editorial allocation of 30 clinical concepts, 27 foundational/safety concepts and three cross-cutting concepts provisionally placed under Other. Questions and cards each use a 10/9/1 allocation. These are study choices, not official weighting or a claim to cover the complete detailed curriculum.
How does the current framework relate to historical society certification?
JASTRO separately identifies Japanese Medical Specialty Board subspecialty information and society-certified specialist information. Its page lists a November 22, 2023 notice concerning abolition and handling of the former JASTRO/JRS-certified examination. Detailed transition provisions are not established here, so historical certification is not presented as an alternative current examination pathway.
What professional level and eligibility context are established?
The 2026 notice requires a Japanese physician license, membership in JRS and JASTRO, specified clinical experience and membership periods, and qualifying specialist training. It describes both curriculum-completion assessment and a separately conditioned equivalent-training route. Applicants should apply the complete current requirements to their circumstances; this guide does not determine individual eligibility.
This guide addresses 日本専門医機構認定放射線治療専門医認定試験 in Japan. It is a physician subspecialty certification examination, distinct from initial medical licensing, radiation diagnosis certification and the historical JASTRO/JRS society-certified examination. The Japanese title is authoritative; the English wording here is descriptive.
Outline used: Public examination outline in the notice dated 2026-04-06 for the third 日本専門医機構認定放射線治療専門医認定試験. The notice specifies the revised March 2025 curriculum guidelines as the examination basis, establishing their use for the 2026 examination rather than an independently verified implementation date. The current notice and its broad scope were opened and read; the detailed curriculum could not be retrieved during this repair and was not read. The generic workbook label 'Japanese Society for Radiation Oncology Certification Exam' is editorially mapped to this current official physician specialist examination while retaining the assigned slug; it is not an evidenced official English examination title or a separate current examination.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Radiation oncology and radiation therapynot stated
1.Why does breast-conserving surgery usually include radiotherapy?
Breast-conserving surgery removes the visible lesion, but microscopic malignant cells may remain elsewhere in the conserved breast. Adjuvant breast irradiation reduces ipsilateral recurrence and is an integral component of breast-conserving treatment for most eligible patients. The decision depends on margins, disease extent and recurrence risk rather than the cosmetic appearance of the operation. Selected omission strategies require specific low-risk circumstances and should not be generalized to all small tumors.
Apply it
A patient with a small invasive breast cancer has clear margins after lumpectomy and wants to preserve her breast. Explain how postoperative irradiation addresses residual microscopic disease and assess whether she meets any established omission criteria.
Common pitfall: Clear surgical margins do not prove that the remaining breast contains no microscopic disease. Lumpectomy alone is not automatically equivalent to breast-conserving treatment with radiotherapy.
2.When does a breast tumor-bed boost add value?
A tumor-bed boost delivers additional dose to the area at greatest risk of local recurrence after breast-conserving surgery. Its value increases when baseline recurrence risk is higher, including in younger patients. Improved local control must be weighed against fibrosis and cosmetic effects. The boost supplements the selected breast irradiation strategy; it does not compensate for an inadequately evaluated positive margin or justify ignoring disease outside the tumor bed.
Apply it
A young patient completing whole-breast irradiation asks whether additional tumor-bed treatment is worthwhile. Compare her recurrence risk with the potential for fibrosis and cosmetic change, and confirm that surgical margins have been appropriately addressed.
Common pitfall: A boost is not simply extra treatment for everyone. Its absolute benefit depends on baseline risk, and increasing dose can worsen late tissue effects.
3.Which patients resemble the evidence population for breast irradiation omission?
CALGB 9343 principally studied women aged at least 70 years with T1, clinically node-negative, estrogen receptor-positive breast cancer, clear lumpectomy margins and tamoxifen treatment. At 10 years, freedom from locoregional recurrence was 98% with irradiation versus 90% without irradiation; overall survival did not differ significantly. Thus, omission exchanges some local control for avoiding radiotherapy. These are named trial criteria, not an official examination eligibility rule. Primary evidence: [CALGB 9343](https://pmc.ncbi.nlm.nih.gov/articles/PMC3691356/).
Apply it
A 75-year-old woman has a 1.4-cm estrogen receptor-positive tumor, clinically negative nodes and clear lumpectomy margins, and plans tamoxifen. Explain that trial-supported omission entails approximately 10% rather than 2% locoregional recurrence at 10 years. Incorporate life expectancy, endocrine-treatment adherence, treatment burden and her preferences.
Common pitfall: Older age alone does not establish suitability. Node-positive disease, involved margins or estrogen receptor-negative disease would weaken direct extrapolation from this population. A nonsignificant overall survival comparison does not establish identical local control or prove survival equivalence.
4.How does regional nodal irradiation differ from breast irradiation?
Breast irradiation treats the conserved breast; regional nodal irradiation deliberately covers selected lymphatic regions at risk. These can include axillary levels I–III, the infraclavicular and supraclavicular regions, and internal mammary nodes. Selection depends on the number and distribution of involved nodes, primary-tumor location, residual disease and the extent of prior axillary surgery. An undissected axilla and an adequately dissected axilla present different residual-risk and lymphedema considerations. Greater nodal burden strengthens the indication for regional treatment, while medial or central disease can strengthen consideration of internal mammary coverage. Each added region changes heart, lung and lymphatic exposure.
Apply it
A patient has a medial breast primary, clear lumpectomy margins and five involved nodes among 15 removed in a level I–II axillary dissection, with no gross residual disease. Whole-breast treatment addresses the conserved breast; the nodal burden also supports regional treatment. Include the remaining upper axillary/infraclavicular and supraclavicular regions in the proposed regional plan and evaluate internal mammary coverage given the medial primary and nodal involvement. Review the operative extent and disease distribution before adding the already dissected level I–II axilla: it need not receive routine comprehensive coverage solely because other nodal regions are treated. Compare heart and lung exposure and lymphedema risk when finalizing the selected volumes.
Common pitfall: Regional nodal irradiation does not mean that every patient requires every nodal region. Incidental axillary dose from breast tangents does not establish deliberate nodal coverage, and a whole-breast DVH cannot answer whether a separately indicated nodal target is covered. Prior surgery informs selection but does not eliminate risk in remaining regional nodes.
5.Which pathological findings strengthen the indication for postmastectomy radiotherapy?
Postmastectomy radiotherapy addresses residual microscopic disease in the chest wall and regional lymphatics. Four or more involved axillary nodes strongly support treatment. Extensive primary disease, such as a tumor larger than 5 cm or invasion of skin or chest wall, and involved surgical margins also strengthen the indication. These findings imply greater residual locoregional risk than a small, node-negative tumor removed with clear margins. One to three involved nodes still warrant assessment of radiotherapy benefit and additional risk factors; they do not define an automatic omission group.
Apply it
Compare a patient with a 2-cm tumor, negative nodes and clear margins with another who has five involved axillary nodes and an involved mastectomy margin. The latter has substantially stronger pathological reasons for chest-wall and regional treatment. With two involved nodes, review tumor size, margin status, lymphovascular invasion and other recurrence-risk features alongside systemic therapy and anticipated toxicity.
Common pitfall: Mastectomy and immediate reconstruction do not erase chest-wall or nodal recurrence risk. Reconstruction affects planning and complications, while the oncological indication follows pathological risk. Avoid treating the threshold of four positive nodes as evidence that one to three positive nodes never benefit.
6.How does START-B illustrate effective breast hypofractionation?
START-B compared 40 Gy in 15 fractions over three weeks with 50 Gy in 25 fractions over five weeks after surgery for early breast cancer. Long-term findings supported comparable locoregional control with acceptable normal-tissue outcomes for the shorter schedule. Breast tumors and late-responding normal tissues show clinically relevant fraction-size sensitivity: increasing dose per fraction increases biological effect per unit physical dose. Reducing the total dose helps balance that increase. Primary evidence: [START long-term results](https://pubmed.ncbi.nlm.nih.gov/24055415/).
Apply it
For postoperative breast irradiation, connect the studied 40-Gy schedule to its treatment setting, target coverage, dose homogeneity and organ-at-risk exposure. Explain that its lower physical total dose does not mean proportionally weaker treatment. The schedule was clinically tested rather than derived merely by shortening the appointment calendar.
Common pitfall: Delivering 50 Gy in 15 fractions would not reproduce START-B's tested comparison and could increase late toxicity. Trial eligibility defines the direct evidence population; broader contemporary indications require their own supporting evidence. Neither the trial nor a biological model licenses arbitrary changes in fraction size, target extent or total dose.
Breast Cancer Treatment (PDQ®)—Health Professional Version · Radiation Biology: A Handbook for Teachers and Students
7.When is lung SBRT a definitive treatment option?
Stereotactic body radiotherapy delivers an ablative dose with high spatial precision and is an established definitive option for medically inoperable early-stage non-small-cell lung cancer. Appropriate staging must support localized disease, and planning must account for respiratory motion and nearby organs. Its rationale is durable local control in patients who cannot safely undergo resection. A small lung lesion alone does not establish suitability without evaluating malignancy, nodal status and anatomical constraints.
Apply it
A patient with severe pulmonary impairment has a peripheral, node-negative early lung cancer and cannot tolerate surgery. Assess definitive SBRT suitability by confirming staging, respiratory motion management and the feasibility of protecting surrounding normal tissues.
Common pitfall: Ablative local treatment does not address unsuspected nodal or distant disease. Small tumor size should not replace staging or assessment of whether the lesion is malignant.
Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
8.How does operability change early lung cancer treatment?
For operable early-stage non-small-cell lung cancer, surgical resection remains an important standard treatment and provides pathological information about the tumor and lymph nodes. SBRT is particularly established when surgery is medically unsuitable. Comparing options requires assessment of pulmonary reserve, cardiovascular risk, anatomy and patient preferences. Strong outcomes in medically inoperable SBRT cohorts do not by themselves establish that surgery and SBRT are interchangeable for every fit surgical candidate.
Apply it
A fit patient with a resectable peripheral lung cancer requests SBRT after hearing about its convenience. Arrange a balanced discussion of surgical and radiation approaches, including operative risk, staging information, local control and the limits of comparative evidence.
Common pitfall: Chronological age alone does not establish inoperability. Conversely, a technically resectable lesion does not mean the patient can physiologically tolerate the required operation.
Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
9.Why does central lung tumor location change SBRT planning?
Central lung tumors lie near structures such as major airways, the esophagus and large vessels, where high doses per fraction can cause serious injury. A schedule appropriate for a peripheral lesion cannot be transferred automatically to central disease. Fractionation and achievable target coverage must be evaluated against location-specific organ constraints. The decisive clue is the spatial relationship between the target and vulnerable structures, not simply whether the tumor is small enough for stereotactic treatment.
Apply it
Two equally sized early lung tumors are considered for SBRT; one abuts a major bronchus. Compare their organ-at-risk relationships and choose a treatment strategy that reflects the central lesion’s greater risk of severe normal-tissue injury.
Common pitfall: Tumor diameter alone does not determine SBRT safety. Meeting a target coverage goal cannot justify exceeding a critical airway or other central-organ tolerance.
Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
10.Why favor concurrent chemoradiation in fit unresectable stage III lung cancer?
In suitable patients with unresectable stage III non-small-cell lung cancer, concurrent chemotherapy and thoracic radiotherapy offer better survival than sequential treatment, at the cost of greater acute toxicity, particularly esophagitis. Chemotherapy treats systemic disease and can enhance radiation effects. Fitness, organ function and treatment-volume burden influence suitability. This is an initial treatment-sequencing decision; subsequent systemic treatment requires its own assessment of disease characteristics, response and eligibility.
Apply it
A patient with unresectable stage III disease has good performance status and adequate organ function. Compare concurrent and sequential treatment, explaining the survival rationale and increased acute toxicity before considering the separate decisions that follow chemoradiation.
Common pitfall: Concurrent treatment is not appropriate solely because disease is stage III. Physiological reserve and toxicity risk can make a sequential approach more reasonable for an individual.
Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
11.When is sequential thoracic chemoradiation reasonable?
Sequential chemotherapy followed by thoracic radiotherapy can be appropriate when a patient with unresectable locally advanced non-small-cell lung cancer cannot tolerate concurrent treatment. Separating modalities can reduce overlapping toxicity, although it sacrifices the population-level advantage associated with concurrent delivery in fitter patients. The decision should distinguish potentially modifiable problems from persistent limitations. It should also preserve a coherent treatment intent rather than allowing an unplanned delay to become an accidental sequential strategy.
Apply it
A patient with unresectable stage III disease has comorbidities that make simultaneous chemotherapy and thoracic irradiation unsafe. Discuss a planned sequential approach, documenting why reduced overlapping toxicity outweighs the expected advantage of concurrent treatment in fitter patients.
Common pitfall: Sequential treatment should be a deliberate clinical choice. An avoidable scheduling delay is not equivalent to selecting a supported sequence after evaluating patient tolerance.
Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
12.How does a superior sulcus lung tumor alter treatment planning?
Superior sulcus tumors can invade the chest wall and structures near the thoracic inlet, making anatomical resectability and multidisciplinary assessment central to treatment selection. Selected resectable cases may receive induction chemoradiation followed by surgery. Nodal status, vertebral or vascular involvement and the feasibility of complete resection influence this pathway. The anatomical syndrome therefore calls for a coordinated local and systemic strategy rather than treating the apical position as an incidental radiological detail.
Apply it
A patient has an apical lung cancer with shoulder pain and suspected chest-wall involvement. Obtain multidisciplinary staging and resectability assessment, then consider whether induction chemoradiation followed by surgery fits the extent of disease and the patient’s fitness.
Common pitfall: An apical tumor is not automatically eligible for trimodality treatment. The possibility of complete resection and the extent of nodal or adjacent-structure involvement remain decisive.
Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
13.Why is brachytherapy central to definitive cervical radiotherapy?
Brachytherapy places radiation sources close to cervical disease, allowing a high central tumor dose with a steep fall-off toward adjacent bladder, rectum and bowel. It is a core component of definitive radiotherapy for many cervical cancers, usually combined with external-beam treatment. External-beam dose escalation does not automatically reproduce its dose distribution or evidence base. Applicator geometry, residual tumor extent and organ positions determine whether an intracavitary approach alone provides adequate coverage.
Apply it
A patient receiving definitive cervical chemoradiation asks to replace brachytherapy with more external-beam fractions. Explain the geometric advantage of brachytherapy and assess whether her residual disease requires intracavitary treatment alone or an additional interstitial component.
Common pitfall: A modern external-beam technique does not inherently replace brachytherapy. Similar nominal prescription doses can conceal very different tumor coverage and adjacent-organ exposure.
Cervical Cancer Treatment (PDQ®)—Health Professional Version
14.Why combine cisplatin with radiotherapy for locally advanced cervical cancer?
Concurrent cisplatin-based chemotherapy improves outcomes when added to radiotherapy for appropriate patients with locally advanced cervical cancer. Its radiosensitizing action complements the local treatment delivered by external-beam irradiation and brachytherapy. Renal function, marrow reserve and general fitness influence whether the usual concurrent approach is tolerable. Chemotherapy strengthens the radiation-based strategy; it does not remove the need for adequate radiation coverage, brachytherapy or careful control of treatment interruptions.
Apply it
A patient with locally advanced cervical cancer has adequate renal function and performance status. Explain why concurrent cisplatin is considered alongside external-beam radiotherapy and brachytherapy, while establishing monitoring for renal, hematological and other treatment-related toxicity.
Common pitfall: Chemotherapy cannot compensate for omitted brachytherapy or inadequate local treatment. Conversely, a standard concurrent agent should not be given without assessing organ function and tolerance.
Cervical Cancer Treatment (PDQ®)—Health Professional Version
15.How can early cervical cancer treatment avoid unnecessary combined morbidity?
Selected early cervical cancers can be treated with surgery or radiation-based approaches, depending on stage, tumor features and patient circumstances. Treatment planning should consider the likelihood that adverse pathological findings would trigger postoperative irradiation or chemoradiation. Combining radical surgery with subsequent radiation can increase morbidity. The aim is not to avoid indicated adjuvant treatment, but to choose an initial strategy that anticipates disease extent and reduces avoidable exposure to multiple radical local treatments.
Apply it
An early cervical cancer has features suggesting a substantial chance of postoperative adjuvant treatment. Compare initial surgical and radiation-based strategies with the multidisciplinary team, including the possible morbidity if radical surgery is followed by pelvic irradiation.
Common pitfall: Avoiding combined treatment is not a reason to withhold indicated postoperative therapy. The opportunity is to improve initial selection using the information available before treatment.
Cervical Cancer Treatment (PDQ®)—Health Professional Version
16.How does imaging guide cervical brachytherapy geometry?
Cross-sectional imaging allows brachytherapy planning to relate applicator position to residual cervical tumor and adjacent organs. An asymmetric or laterally extensive residual target may not be adequately covered by an intracavitary arrangement alone without excessive organ dose. Adding interstitial capability can improve geometric access to disease. The key decision is whether the source arrangement can cover the actual target safely, rather than assuming every cervical tumor is centered symmetrically around a standard applicator.
Apply it
Imaging before a cervical brachytherapy fraction shows substantial unilateral residual disease beyond the expected intracavitary high-dose region. Review whether a combined intracavitary–interstitial approach can improve coverage while respecting bladder, rectal and bowel exposure.
Common pitfall: Increasing all dwell times cannot reliably correct a geometric miss. It can raise normal-organ dose while still failing to cover laterally displaced disease adequately.
Cervical Cancer Treatment (PDQ®)—Health Professional Version
17.What did the historical Patel cervical HDR–LDR comparison actually show?
Patel and colleagues reported similar local control with the historical low-dose-rate and high-dose-rate cervical brachytherapy treatments studied. Overall rectal complications were significantly more frequent with LDR than HDR: 19.9% versus 6.4%. Grade 3–4 complications were reported in 2.4% versus 0.4%, respectively, without a statistically significant difference. These findings distinguish tumor control, overall rectal morbidity and severe complications; they do not support one undifferentiated claim that all outcomes were equivalent.
Apply it
When discussing this trial, state the direction and magnitude of each finding. The absolute difference in overall rectal complications was 13.5 percentage points in favor of HDR. Explain separately that the severe-complication comparison did not demonstrate a statistically significant difference, despite numerically fewer events with HDR.
Common pitfall: Nonsignificance does not prove equal severe-toxicity risks. Event frequency, precision and study design affect what can be concluded. Dose rate also changes opportunities for repair during irradiation, so physical doses cannot be compared without considering schedules. Apply the results to the historical treatments studied rather than automatically extending them to all modern brachytherapy techniques.
Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial · Cervical Cancer Treatment (PDQ®)—Health Professional Version
18.What risk features and monitoring distinguish prostate active surveillance from observation?
In the AUA/ASTRO localized prostate cancer framework, a low-risk example is PSA below 10 ng/mL, Grade Group 1 and clinical stage T1–T2a. Active surveillance is the preferred management option for many patients in this category. It preserves the opportunity for curative treatment while using serial PSA assessment and repeat prostate biopsy to detect clinically important change. This is an explicitly identified international guideline framework, not a universal Japanese eligibility rule. Primary guidance: [AUA/ASTRO localized prostate cancer guideline](https://www.auanet.org/documents/guidelines/pdf/localized%20prostate%20cancer%20guideline%20050522.pdf).
Apply it
A patient with PSA 6 ng/mL, Grade Group 1 and cT1c disease can discuss surveillance if his life expectancy, preferences and ability to complete monitoring support it. Explain that repeat biopsy may reveal upgrading or greater disease extent, prompting reconsideration of surgery or radiotherapy. A PSA rise should trigger reassessment rather than automatically determine treatment.
Common pitfall: Low PSA alone cannot establish low risk when grade or stage is unfavorable. MRI can assist surveillance but does not replace periodic biopsy. Symptom-directed observation differs because it generally prioritizes avoiding intervention in patients whose life expectancy limits the likely benefit of curative treatment.
Prostate Cancer Treatment (PDQ®)—Health Professional Version
19.How do prostate cancer risk groups determine ADT use and duration with definitive radiotherapy?
The 2022 AUA/ASTRO international guideline advises against routine androgen deprivation therapy with radiotherapy for low- or favorable intermediate-risk disease. It recommends short-course ADT for four to six months with unfavorable intermediate-risk radiotherapy and long-course ADT for 18 to 36 months with high-risk radiotherapy. These are international clinical recommendations, not Japanese examination rules. ADT suppresses androgen-driven tumor activity and complements irradiation, while adding sexual, metabolic and skeletal harms. Primary guidance: [2022 AUA/ASTRO guideline](https://www.auanet.org/documents/guidelines/pdf/localized%20prostate%20cancer%20guideline%20050522.pdf).
Apply it
Compare cT1c, PSA 7 ng/mL, Grade Group 1 disease with cT2b, PSA 12 ng/mL, Grade Group 3 disease and cT3a, PSA 25 ng/mL, Grade Group 4 disease. These illustrate low, unfavorable intermediate and high risk, respectively: routine ADT is generally omitted, four to six months is recommended, and 18 to 36 months is recommended with definitive radiotherapy. Assess cardiovascular and skeletal health before treatment.
Common pitfall: A low PSA does not override adverse grade or stage. Do not apply high-risk ADT duration to every intermediate-risk patient or confuse definitive-treatment recommendations with postoperative salvage recommendations.
Prostate Cancer Treatment (PDQ®)—Health Professional Version
20.How do disease risk, urinary function and anatomy determine the role of prostate brachytherapy?
The 2022 AUA/ASTRO international guideline includes permanent LDR or temporary HDR implant monotherapy among radiation options for appropriately selected low- or favorable intermediate-risk prostate cancer. For unfavorable intermediate- or high-risk disease, combined external-beam radiotherapy and a brachytherapy boost with risk-appropriate ADT is an option. Risk determines the oncological strategy; urinary function and anatomy determine whether an implant is suitable. These recommendations are not Japanese examination rules. Primary guidance: [AUA/ASTRO radiation principles](https://www.auajournals.org/doi/full/10.1097/JU.0000000000002759).
Apply it
A patient with cT1c disease, PSA 7 ng/mL, Grade Group 2 and two of 12 positive cores illustrates favorable intermediate risk and may consider implant monotherapy. A patient with cT2b disease, PSA 12 ng/mL and Grade Group 3 illustrates unfavorable intermediate risk and may consider external-beam treatment plus a brachytherapy boost and ADT. Separately assess obstruction, gland geometry and procedural feasibility in each.
Common pitfall: Good urinary function does not justify implant monotherapy for every risk group. Conversely, an oncological indication for a boost does not establish procedural suitability when marked obstruction or unfavorable anatomy raises morbidity.
Prostate Cancer Treatment (PDQ®)—Health Professional Version
21.When should salvage radiotherapy be considered after a rising postprostatectomy PSA?
Salvage radiotherapy after prostatectomy is more effective when delivered at lower PSA levels. The 2024 AUA/ASTRO/SUO guideline recommends providing salvage radiotherapy while PSA is no greater than 0.5 ng/mL when salvage treatment is being considered. Selected patients at high risk of progression may be offered treatment below 0.2 ng/mL. These are treatment-timing recommendations, not instructions to wait until PSA reaches either threshold. Assessment includes PSA kinetics, pathological grade and stage, margins, imaging, life expectancy and treatment-related harms.
Apply it
A patient has a confirmed PSA rise to 0.3 ng/mL after prostatectomy and a negative molecular PET scan. Evaluate prostate-bed salvage promptly: a negative scan cannot exclude microscopic disease and should not automatically justify withholding or delaying treatment. Rapid PSA doubling, high Grade Group or seminal-vesicle involvement can strengthen concern about progression.
Common pitfall: Waiting for symptoms or a visible pelvic mass can sacrifice an earlier salvage opportunity. Conversely, a single detectable ultrasensitive PSA result below conventional biochemical-recurrence criteria requires confirmation of a rising trend before treatment. Imaging informs treatment extent but has limited sensitivity for very small-volume recurrence.
Prostate Cancer Treatment (PDQ®)—Health Professional Version · STPC%20Unabridged%20Final.pdf
22.How do acute and late bowel toxicities differ after pelvic radiotherapy?
Acute bowel injury reflects damage to rapidly proliferating intestinal epithelium and can produce watery diarrhea, cramping and tenesmus during pelvic treatment. Initial management addresses hydration, nutrition and diarrhea, including loperamide for uncomplicated symptoms. Late injury months to years afterward involves vascular damage and fibrosis and may cause bleeding, stenosis, obstruction or fistula. Recurrent malignancy must also be excluded. Clinical reference: [NCI Gastrointestinal Complications PDQ](https://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq).
Apply it
During cervical chemoradiation, mild watery diarrhea with preserved intake calls for hydration assessment, dietary adjustment and symptom control. Fever, substantial dehydration, severe pain or bleeding requires prompt investigation for complications and alternative causes, including infection. Months after prostate or anal irradiation, persistent rectal bleeding, weight loss or obstructive symptoms requires evaluation rather than automatic attribution to expected acute toxicity.
Common pitfall: Timing suggests a mechanism but does not establish the diagnosis. Severe or persistent symptoms require investigation; continuing antidiarrheals alone can miss obstruction, infection or recurrent cancer.
Cervical Cancer Treatment (PDQ®)—Health Professional Version · Prostate Cancer Treatment (PDQ®)—Health Professional Version · Anal Cancer Treatment (PDQ®)—Health Professional Version
23.Which concurrent chemotherapy supports definitive treatment of anal squamous carcinoma?
For most patients receiving definitive chemoradiation for localized anal squamous carcinoma, the 2025 ASTRO guideline recommends concurrent mitomycin plus fluorouracil or capecitabine. These agents enhance the effect of radiation on tumor cells, supporting local control and organ preservation. Cisplatin is a conditional alternative to mitomycin, rather than the usual default. This is international clinical guidance. Primary guidance: [ASTRO anal cancer guideline](https://pubmed.ncbi.nlm.nih.gov/40023252/).
Apply it
For nonmetastatic anal canal squamous carcinoma, discuss radiotherapy with concurrent mitomycin and a fluoropyrimidine, assessing marrow reserve, renal function and treatment tolerance. Explain that capecitabine is an alternative to fluorouracil within this combination; it does not replace mitomycin. If mitomycin is unsuitable, assess a conditional cisplatin-based alternative through multidisciplinary review.
Common pitfall: Unspecified chemotherapy does not identify the supported regimen. Do not treat conditional cisplatin substitution as a universally preferred replacement, or extrapolate a rectal adenocarcinoma regimen solely from anatomical proximity.
24.How does ACT II inform response-assessment timing after anal cancer chemoradiation?
The ACT II response analysis assessed patients at 11, 18 and 26 weeks from the start of chemoradiation. Many patients without a complete response at the earliest assessment achieved one by 26 weeks. Continued tumor regression therefore matters: an early residual abnormality does not by itself establish treatment failure or justify immediate salvage surgery. The timing anchor is treatment initiation, not treatment completion. Primary evidence: [ACT II response analysis](https://pubmed.ncbi.nlm.nih.gov/28209296/).
Apply it
At an early assessment, a residual anal lesion is progressively shrinking and symptoms are improving. Document serial examination findings and continue structured reassessment, using the ACT II timetable to explain why complete regression may take months. Assess the primary site and regional nodes, and investigate any new enlargement or worsening symptoms promptly.
Common pitfall: The 26-week assessment is not permission to wait despite progression. Growing tumor, new nodal disease or other concerning deterioration requires timely investigation and appropriate confirmation for salvage planning. Persistently suspicious disease also needs evaluation; delayed response should not become indefinite observation without a defined reassessment plan.
25.When does anal cancer require surgical salvage?
Persistent or recurrent localized anal cancer after definitive chemoradiation may require salvage surgery, commonly abdominoperineal resection when anatomically appropriate. The decision follows confirmation and staging of suspected failure, because inflammatory change and delayed regression can mimic residual tumor. Assessment must determine whether disease remains potentially resectable and whether distant spread changes treatment intent. Salvage surgery is a response to established oncological failure, not an automatic consequence of any early post-treatment irregularity.
Apply it
A patient develops a biopsy-confirmed localized anal recurrence after an initial complete response to chemoradiation. Restage for distant disease, assess resectability and fitness, and discuss salvage surgery with clear explanation of functional and stoma-related consequences.
Common pitfall: A suspicious examination alone may require clarification before irreversible salvage. However, confirmed recurrent disease should not be dismissed as delayed radiation-related healing.
26.Which conventional schedules support initial palliation of uncomplicated painful bone metastases?
Representative conventional schedules for initial treatment of symptomatic bone metastases include 8 Gy once, 20 Gy in five fractions, 24 Gy in six fractions and 30 Gy in ten fractions. The randomized comparison of 8 Gy once versus 30 Gy in ten fractions found similar pain relief, while retreatment was more frequent after the single fraction. Thus, additional fractions do not necessarily improve initial analgesic response. Selection should incorporate prognosis, travel burden, anatomy, patient preferences and the likelihood of needing another treatment.
Apply it
For a previously unirradiated, painful bone metastasis without instability, impending fracture or cord compression, explain the convenience of 8 Gy once alongside its greater retreatment likelihood compared with 30 Gy in ten fractions. A patient facing difficult travel may reasonably prioritize the single visit after understanding both endpoints.
Common pitfall: These initial-treatment examples should not be copied automatically into reirradiation, where prior dose and organ tolerance matter. Mechanical instability or impending fracture may require stabilization, and spinal cord or cauda equina compression requires urgent multidisciplinary assessment. Pain relief, structural safety and retreatment are separate outcomes.
External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline · Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases
27.What immediate actions are required for suspected metastatic spinal cord compression with neurological deficits?
New weakness, gait disturbance or bladder dysfunction with suspected spinal metastatic disease is an oncological emergency. UK NICE NG234 recommends spinal MRI as soon as possible and within 24 hours, and dexamethasone 16 mg orally or an equivalent parenteral dose promptly for neurological symptoms or signs. Continue 16 mg daily while awaiting surgery or radiotherapy, then reduce gradually after surgery or when radiotherapy starts. These are UK clinical recommendations, not Japanese regulatory requirements.
Apply it
For vertebral metastases with new leg weakness and urinary symptoms, arrange emergency assessment, urgent spinal MRI and immediate dexamethasone. Start immobilisation without delay when neurological findings suggest spinal instability, and consider it for substantial movement-related pain. Obtain urgent spine-surgical and radiation assessment; selected patients benefit from decompression and stabilization followed by radiotherapy.
Common pitfall: Do not delay dexamethasone until MRI when neurological symptoms or signs suggest compression. Analgesic improvement does not exclude compression, and radiotherapy cannot correct mechanical instability by itself. If imaging excludes spinal metastases and compression, discontinue dexamethasone rather than continuing an unsupported course.
Recommendations | Spinal metastases and metastatic spinal cord compression | Guidance | NICE · External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline
28.Why consider radiotherapy after surgery for bone metastases?
Surgery can stabilize an affected bone or decompress neural structures without eliminating all local malignant tissue. Postoperative radiotherapy addresses residual local disease and is recommended in relevant bone-metastasis settings. Planning requires coordination around wound recovery, operative findings, hardware and the region at risk. The surgical and radiation components solve different parts of the problem: mechanical or neurological intervention does not automatically provide durable oncological control of the treated site.
Apply it
A patient undergoes fixation of a pathological fracture through metastatic disease. After recovery assessment, coordinate postoperative radiotherapy planning with the surgical team, reviewing operative extent, residual disease, hardware and the patient’s overall goals of care.
Common pitfall: Successful fixation does not mean the metastasis has been eradicated. Conversely, postoperative irradiation must be coordinated with healing rather than scheduled without surgical context.
29.Which patients may benefit from bone-metastasis SBRT?
SBRT may offer advantages for selected patients with symptomatic bone metastases who have favorable performance status and an appropriate anatomical and clinical setting. Selection must consider neurological symptoms, need for surgery, prior irradiation and the ability to meet nearby organ constraints. Its greater technical intensity is justified by the expected clinical benefit, not by technological availability. Conventional palliative radiotherapy remains effective and may better suit patients whose prognosis or treatment burden argues for a simpler approach.
Apply it
A patient with good performance status has a symptomatic bone metastasis without neurological compromise or a surgical indication. Compare SBRT with conventional palliation using expected benefit, prognosis, prior treatment, normal-organ constraints and the practical burden of preparation.
Common pitfall: SBRT should not delay urgent decompression or stabilization. A more conformal dose distribution does not itself establish that the patient will benefit from an ablative approach.
30.Why distinguish mechanical instability from tumor-related bone pain?
Radiotherapy can reduce pain caused by metastatic tumor activity, but it does not immediately restore structural strength to an unstable bone. Pain provoked by weight-bearing, deformity or neurological findings can indicate a mechanical problem requiring surgical assessment. Choosing a radiation schedule before evaluating stability risks missing the intervention needed to prevent fracture or preserve function. The relevant decision separates tumor control from the biomechanical consequences of bone destruction, even when both contribute to symptoms.
Apply it
A patient with a destructive femoral metastasis reports severe pain when standing but relative comfort at rest. Obtain assessment for fracture risk and stabilization needs before treating the presentation as uncomplicated pain suitable for radiotherapy alone.
Common pitfall: Painful bone metastases are not a single clinical category. Good expected radiation pain relief does not remove the need to evaluate impending fracture or spinal instability.
Radiation basic medicine and radiation safety managementnot stated
31.What does the gross tumor volume represent?
The gross tumor volume is the demonstrable extent of malignant disease identified through examination, imaging or other clinical information. It describes known gross disease, not a margin for invisible extension or setup uncertainty. Its definition depends on the imaging modality and clinical context, and it may be absent after complete surgical removal. Distinguishing gross disease from other target components prevents a visible-lesion contour from being mistaken for the complete volume requiring therapeutic coverage.
Apply it
A planning scan shows a clearly visible lung mass and a separate enlarged node judged malignant. Delineate the demonstrable disease as gross tumor volumes, then address microscopic extension and geometric uncertainties through the appropriate additional target definitions.
Common pitfall: A gross tumor contour does not include every necessary treatment margin. Enlarging it informally mixes biological disease extent with uncertainties that should be identified separately.
Radiation Oncology Physics: A Handbook for Teachers and Students
32.How does the clinical target volume address microscopic disease?
The clinical target volume includes known disease and tissue considered at risk of microscopic malignant involvement. It is a clinical and anatomical judgment informed by patterns of spread, pathology and barriers to extension. It is not necessarily a uniform geometric expansion around the gross tumor. In postoperative treatment, a clinically meaningful target can exist despite no visible tumor. The discriminating feature is suspected disease distribution, whereas motion and setup uncertainty belong to other planning concepts.
Apply it
After resection, no gross disease is visible, but pathology identifies a tumor bed and regional tissues at meaningful microscopic risk. Define a clinical target from operative and pathological information rather than concluding that no target exists.
Common pitfall: A uniform expansion can cross anatomical barriers unnecessarily or miss a relevant route of spread. Microscopic-risk assessment should not be replaced by a convenient contouring shortcut.
Radiation Oncology Physics: A Handbook for Teachers and Students
33.How does an internal target volume account for motion?
An internal target volume accounts for expected changes in the clinical target’s position, size or shape within the patient, such as respiratory motion. Motion assessment can use information from appropriately acquired imaging, including respiratory-correlated datasets. This differs from uncertainty in positioning the patient relative to the treatment machine. An internal-motion approach should match the actual delivery strategy, because free-breathing, breath-hold and gating can produce different residual motion envelopes and uncertainties.
Apply it
A lower-lobe lung tumor moves substantially during breathing. Review motion-resolved imaging and the proposed delivery method, then define the internal-motion allowance appropriate to that strategy before adding separate allowances for residual setup uncertainty in the treatment plan.
Common pitfall: A single static scan can underestimate motion. Conversely, combining a full free-breathing envelope with an unrelated motion-control strategy can add unnecessary normal-tissue exposure.
Radiation Oncology Physics: A Handbook for Teachers and Students
34.Why is the planning target volume a geometric concept?
The planning target volume supports reliable dose delivery despite geometrical uncertainties such as setup variation and internal movement. It is a planning construct rather than an additional layer of malignant tissue. Margin selection should reflect measured uncertainty and the imaging and correction strategy used. Better image guidance can reduce some uncertainty components but does not automatically eliminate all of them. The key distinction is between defining disease and ensuring that the intended disease volume receives treatment.
Apply it
Daily image guidance corrects a reproducible setup shift in a pelvic treatment. Review residual random error, organ deformation and intrafraction movement before modifying the planning margin, rather than setting the margin to zero because imaging is performed.
Common pitfall: Image guidance does not erase deformation or intrafraction motion. A smaller planning margin requires evidence about residual uncertainty, not simply access to better imaging technology.
Radiation Oncology Physics: A Handbook for Teachers and Students
35.What can a cumulative dose-volume histogram reveal?
A cumulative dose-volume histogram shows the volume receiving at least each specified dose. D95% is the dose received by at least 95% of the specified structure and is reported in Gy; the volume here is relative. V20 Gy is the volume receiving at least 20 Gy and must be reported as either a relative percentage or an absolute volume such as cm³. D2 cm³ is the dose received by the hottest 2 cm³ of a structure, reported in Gy, and is a near-maximum metric rather than the maximum point dose. Always identify the structure, units and volume convention.
Apply it
In a hypothetical 60-Gy plan, PTV D95% = 57 Gy means that 95% of the PTV receives at least 57 Gy, which is 95% of the prescription. For a separately specified 1,000-cm³ organ contour, V20 Gy = 25% means 250 cm³ receives at least 20 Gy. An organ D2 cm³ of 45 Gy means the hottest 2 cm³ receives at least 45 Gy. These values illustrate interpretation; they are not clinical acceptance constraints. Even if a plan meets its actual protocol metrics, inspect spatial dose: the same D95% can conceal a cold region beside gross disease in one plan and at a less concerning peripheral margin in another.
Common pitfall: Do not read D95% as the dose to the hottest 95% point by point or confuse V20 Gy = 25% with 25 cm³. A cumulative DVH loses spatial information and cannot locate a hot or cold region. Acceptable summary metrics therefore require confirmation against anatomy, target extent and the applicable clinical constraints.
Radiation Oncology Physics: A Handbook for Teachers and Students
36.How does distance affect point-source intensity?
For an ideal point source in free space, intensity varies inversely with the square of distance. Doubling distance reduces intensity to one quarter; reducing distance to half increases it fourfold. The relationship is useful for geometric reasoning and selected dosimetric calculations, but patient dose also depends on attenuation, scattering and source geometry. Applying the law requires identifying the relevant source-to-point distances and stating which physical effects are intentionally excluded from the calculation.
Apply it
In an idealized exercise, a detector moves from 100 cm to 150 cm from a point source. Calculate the intensity ratio as (100/150)², approximately 0.44, while holding source strength and all other conditions unchanged.
Common pitfall: Distance ratios must be squared in the correct direction. An inverse-square estimate alone is not a complete calculation of dose inside a heterogeneous patient.
Radiation Oncology Physics: A Handbook for Teachers and Students
37.Why do megavoltage photon beams have a buildup region?
Megavoltage photons transfer energy largely through secondary electrons, which travel before depositing their energy. Near the surface, electron fluence builds with depth, producing a dose maximum beneath the surface and a skin-sparing effect under suitable conditions. Surface dose still depends on beam energy, field geometry, contamination and materials near the skin. Bolus deliberately changes this situation by bringing buildup into added material, which can increase dose to a superficial target.
Apply it
A superficial chest-wall target risks inadequate skin dose with a megavoltage photon plan. Evaluate whether bolus is needed to modify buildup, and check the resulting target coverage and skin exposure rather than assuming all superficial tissue receives prescription dose.
Common pitfall: Skin sparing does not mean zero skin dose. Bolus also changes dose distribution and toxicity, so its use should follow the intended superficial-target coverage.
Radiation Oncology Physics: A Handbook for Teachers and Students
38.Why do tissue heterogeneities complicate dose calculation?
Lung, bone and air cavities alter photon interactions, attenuation, scattering and secondary-electron transport compared with a uniform water medium. These changes can be particularly important near interfaces and in small fields where charged-particle equilibrium may not hold. A dose algorithm must therefore be suitable for the geometry and materials being treated. A plan’s apparent numerical precision cannot compensate for a calculation model that inadequately represents the relevant physical conditions.
Apply it
A small lung target lies beside a large low-density region. Review whether the commissioned calculation algorithm and beam model adequately handle the field size and tissue interfaces before trusting target dose estimates or comparing highly conformal plans.
Common pitfall: A density correction alone may not capture all transport effects. Agreement in a large homogeneous phantom does not establish accuracy for every small heterogeneous treatment geometry.
Radiation Oncology Physics: A Handbook for Teachers and Students
39.How does inverse planning shape an IMRT dose distribution?
Inverse planning searches for beam intensities that satisfy specified target and organ objectives within a mathematical optimization framework. The result depends on objective definitions, priorities, beam arrangement and achievable geometry. An optimizer does not independently determine the clinically correct trade-off or recognize every important anatomical issue. A high-quality plan requires review of spatial coverage, organ doses and delivery feasibility, with objectives revised when the resulting distribution fails the intended clinical balance.
Apply it
An IMRT plan meets a heavily weighted organ objective but leaves part of the clinical target undercovered. Review the competing objectives and spatial relationship, then revise the optimization according to an explicitly justified clinical trade-off.
Common pitfall: An optimization score is not a clinical outcome measure. A mathematically successful solution can still be unacceptable when objectives are incomplete or incorrectly prioritized.
Radiation Oncology Physics: A Handbook for Teachers and Students
40.Which uncertainties can image guidance actually correct?
Image guidance compares treatment-day anatomy with the planning reference and can support corrections for selected positioning errors. A rigid couch shift can correct translation but cannot necessarily resolve organ deformation, differential motion or anatomical changes that alter dose calculation. Registration must also use a clinically appropriate reference, since matching bone may not align a mobile soft-tissue target. The decisive question is whether the observed discrepancy is correctable within the available treatment workflow.
Apply it
Daily imaging shows good pelvic bone alignment but a displaced soft-tissue target because of different organ filling. Assess preparation and target position directly instead of assuming that a bone match guarantees target coverage with the original plan.
Common pitfall: Registration is not automatically correct because software produces a match. The chosen anatomy and correction model must correspond to the target and the actual discrepancy.
Radiation Oncology Physics: A Handbook for Teachers and Students
41.Why is brachytherapy sensitive to source positioning?
Brachytherapy dose changes rapidly with distance from the source, so small positional errors can produce substantial local dose differences. Source strength, dwell positions, dwell times and applicator reconstruction all contribute to the calculated distribution. The steep gradient that protects nearby tissue also makes geometrical accuracy essential. Verification must connect the imaged applicator to the actual source path and treatment delivery, rather than relying only on a visually attractive isodose display.
Apply it
A brachytherapy plan has acceptable dose-volume metrics, but applicator reconstruction is uncertain by several millimeters near the rectum. Resolve the geometry and source-path verification before delivery because a small discrepancy may materially alter local organ dose.
Common pitfall: Steep dose fall-off is both an advantage and a vulnerability. Good optimization cannot rescue an incorrectly reconstructed applicator or an erroneous source position.
Radiation Oncology Physics: A Handbook for Teachers and Students
42.Why does oxygen increase sensitivity to low-LET radiation?
Oxygen can chemically fix radiation-induced damage produced through free-radical reactions, making that damage less readily reversible. Hypoxic cells are therefore more resistant than well-oxygenated cells to low-linear-energy-transfer radiation under comparable conditions. Reoxygenation between fractions can improve the sensitivity of surviving tumor cells. The effect is a biological property of the irradiated microenvironment; it should not be confused with simply increasing the physical dose delivered by the treatment machine.
Apply it
A tumor contains poorly oxygenated regions despite adequate planned dose coverage. Explain why these cells may survive low-LET irradiation more readily and how changes in oxygenation between fractions can influence the biological response to a fractionated course.
Common pitfall: A homogeneous physical dose does not ensure a homogeneous biological response. Hypoxia-related resistance is not evidence that the planning system calculated the dose incorrectly.
43.What does the linear-quadratic survival model describe?
The linear-quadratic model expresses surviving fraction as exp[−(αD + βD²)] for an acute dose under its simplifying assumptions. The linear and quadratic terms describe components of dose-dependent cell killing, and the α/β ratio indicates where their contributions are equal. A lower α/β implies greater sensitivity to fraction size within the model. It is a useful framework for comparing schedules, but it does not automatically incorporate repopulation, hypoxia or every high-dose-per-fraction behavior.
Apply it
Two tissues receive the same total dose in different fraction sizes. Use their assumed α/β values to predict which tissue’s modeled response changes more with fraction size, while stating that the calculation omits time and oxygenation effects.
Common pitfall: The model’s parameters and assumptions matter. A numerical result is not a validated clinical equivalence when the schedule or biological setting lies outside reliable application.
44.How is biologically effective dose calculated?
With complete repair between fractions and no explicit time correction, biologically effective dose is BED = nd[1 + d/(α/β)], where n is fraction number and d is dose per fraction. BED must be labeled with the assumed α/β because tumor and late-tissue comparisons can differ. It is a model-based comparison, not an absorbed dose measurement. Different schedules can be compared meaningfully only when their assumptions, biological endpoint and relevant timing conditions are made explicit.
Apply it
For a hypothetical 30 Gy in 10 fractions and α/β = 10 Gy, calculate BED as 30 × (1 + 3/10) = 39 Gy₁₀, assuming complete interfraction repair and no correction for overall treatment time.
Common pitfall: BED values calculated with different α/β assumptions cannot be compared as though they describe the same endpoint. The result is not a treatment prescription.
45.How does EQD2 differ from BED?
EQD2 expresses a modeled biological effect as the total dose that would produce the same effect using 2 Gy fractions. Under the basic linear-quadratic assumptions, EQD2 = BED/[1 + 2/(α/β)]. BED and EQD2 are related but numerically different quantities. Both require the same stated α/β and endpoint. Neither calculation by itself accounts for spatial dose variation, incomplete repair, repopulation or uncertainty in combining exposures from separate treatment courses.
Apply it
A hypothetical schedule has BED = 39 Gy₁₀. Divide by 1 + 2/10 to obtain EQD2 = 32.5 Gy for that assumed endpoint, and explain why 39 Gy₁₀ should not be reported as 39 Gy EQD2.
Common pitfall: BED and EQD2 are not interchangeable labels. Summing converted numbers also does not resolve anatomical overlap, recovery or other uncertainties in a reirradiation decision.
46.Why does repair time matter between radiation fractions?
Cells can repair some sublethal radiation damage between exposures, reducing the biological effect compared with closely spaced doses that allow incomplete repair. This is one reason fractionation can spare normal tissues. When multiple fractions are delivered within a day, the interval becomes biologically important. A schedule comparison that assumes complete repair may underestimate effect if fractions are too closely spaced, particularly for tissues with slower repair components.
Apply it
A department proposes moving two planned fractions unusually close together to accommodate scheduling. Assess whether the interval preserves the repair assumptions of the regimen before approving the change, rather than treating fraction timing as an administrative detail.
Common pitfall: Equal total dose and fraction number do not guarantee equal biological effect when spacing differs. A BED calculation assuming full repair cannot justify arbitrary compression.
47.Why can prolonging overall treatment time reduce tumor control?
Surviving tumor clonogens can proliferate during a radiotherapy course, and accelerated repopulation can become important in some tumors. Unnecessary prolongation may therefore reduce the effective antitumor impact of a schedule even when the prescribed physical dose is eventually completed. The magnitude depends on tumor biology and timing. Managing an interruption requires balancing this risk against normal-tissue tolerance and the cause of the break; compensation cannot be determined from total dose alone.
Apply it
A curative course develops an avoidable multi-day interruption. Review the tumor’s time sensitivity, elapsed treatment and normal-tissue limits, then use the department’s clinical interruption process to decide whether and how the schedule should be adjusted.
Common pitfall: Completing every fraction does not necessarily erase the consequence of an extended course. Conversely, adding dose or compressing fractions without biological assessment can increase toxicity.
48.How does cell-cycle redistribution affect radiosensitivity?
Radiosensitivity varies across the cell cycle, with mitosis and G2 generally more sensitive and late S phase relatively resistant to low-LET radiation. After an exposure, surviving cells can progress into different phases before subsequent fractions. This redistribution contributes to the biological rationale for fractionation. It is a population-level principle rather than a promise that every resistant cell will become sensitive at the next treatment, and it operates alongside repair, repopulation and reoxygenation.
Apply it
A learner assumes that cells surviving one fraction are permanently resistant. Use cell-cycle progression to explain why later fractions may encounter a different sensitivity distribution, while distinguishing redistribution from changes in oxygenation or repair of radiation injury.
Common pitfall: Redistribution is not the same process as reoxygenation. Both can alter sensitivity between fractions, but they arise from different biological changes in surviving cells.
49.How does high LET alter radiation response?
High-linear-energy-transfer radiation deposits energy more densely along particle tracks and can produce complex damage that is harder for cells to repair. Relative biological effectiveness depends on radiation quality, dose, tissue and the endpoint measured; it is not a universal constant. Oxygen dependence generally decreases as LET increases. These principles explain why equal absorbed doses from different radiation qualities need not have equal biological effects, while also cautioning against assigning one RBE to every situation.
Apply it
Two experimental exposures deliver the same absorbed dose with different radiation qualities. Compare their expected biological effects using LET and the specified endpoint, and avoid assuming that equal gray values imply equal cell killing or normal-tissue injury.
Common pitfall: RBE belongs to a defined comparison and endpoint. Treating it as an invariant material property can misrepresent dose, tissue and fractionation dependence.
50.What does clonogenic survival measure?
Clonogenic survival measures whether a cell retains the capacity to produce a sustained colony after treatment. Radiation can eliminate reproductive capacity without causing immediate visible cell disintegration. This distinction helps explain why tumor shrinkage may lag behind effective cell killing and why an early anatomical assessment does not always capture biological response. Survival curves describe probabilities across cell populations, not a direct count of how many tumor cells vanish immediately after irradiation.
Apply it
A treated lesion has not immediately decreased in size, and a patient worries that no cancer cells were affected. Explain reproductive cell death and why clinical response assessment must consider the expected timing and behavior of that particular tumor.
Common pitfall: Persistent size alone is not proof of viable clonogens. Equally, a biological explanation for delayed shrinkage must not replace investigation of clinically progressive disease.
51.What makes a medical radiation exposure justified?
Justification asks whether the expected clinical benefit of a medical exposure outweighs its radiation-related detriment, considering suitable alternatives and the individual patient. A technically excellent treatment can still be unjustified if it lacks an appropriate indication. This decision precedes optimization, which concerns how an indicated exposure is delivered. The IAEA framework provides international principles; its terminology should not be treated as a substitute for the specific legal and regulatory requirements applicable in Japan.
Apply it
A proposed additional planning scan duplicates information that is already adequate for the treatment decision. Assess whether it adds a meaningful clinical benefit before focusing on reducing its dose or improving its acquisition parameters for this patient.
Common pitfall: Low dose alone does not justify an unnecessary exposure. Optimization cannot convert a procedure with no meaningful expected clinical benefit into an appropriate one.
52.How does optimization work in therapeutic medical exposure?
Optimization in radiotherapy seeks delivery of the intended tumor dose while keeping normal-tissue exposure consistent with the treatment’s purpose and acceptable risk. It does not mean minimizing every dose regardless of tumor control. Target coverage, dose accuracy, organ protection and reliable delivery must be balanced together. A plan that lowers an organ dose by creating an unjustified target miss may be less optimized clinically, even if one numerical safety metric appears improved.
Apply it
A revised plan reduces rectal exposure but substantially undercovers a prostate target without a clinical reason. Compare the full benefit–harm balance and revise the plan rather than accepting the lower organ dose as automatic evidence of optimization.
Common pitfall: The lowest normal-organ dose is not always the best plan. Optimization must preserve the intended therapeutic objective and an explicitly justified balance of competing risks.
53.Why do patient exposures differ from occupational dose limits?
International radiation-protection standards distinguish patients’ justified medical exposures from occupational and public exposure. Occupational and public dose limits are not applied as caps on a patient’s prescribed therapeutic exposure, because doing so could prevent the intended medical benefit. Patient protection instead relies on justification, optimization and prevention of unintended exposure. This distinction does not remove normal-tissue constraints or quality assurance, and international standards must not be presented as identical to every jurisdiction’s legislation.
Apply it
A trainee argues that a therapeutic prescription is impermissible because it exceeds an occupational annual dose limit. Explain why the categories differ, then redirect the assessment toward clinical justification, intended dose, organ constraints and protection from unintended exposure.
Common pitfall: Exemption from occupational-style patient dose limits does not imply unlimited treatment. Clinical tolerance, prescription accuracy and rigorous safety processes remain essential to patient protection.
54.Why is commissioning different from routine quality assurance?
Commissioning establishes that a new or substantially changed system is characterized, modeled and suitable for its intended clinical use. Routine quality assurance checks continued performance against an established baseline. A stable but incorrect beam model can pass consistency checks if the baseline itself is wrong. Commissioning therefore requires broad validation of relevant conditions, supported by appropriate independent checks, before patients are exposed through the new workflow.
Apply it
A newly installed planning model reproduces its own reference output but has not been tested across representative field sizes and clinical geometries. Complete commissioning and independent validation before release rather than treating repeated agreement with one baseline as sufficient.
Common pitfall: Consistency is not the same as accuracy. Routine checks against an erroneous baseline can repeatedly confirm the same underlying commissioning error without detecting it.
Radiation Protection in Medicine: Setting the Scene for the Next Decade · Radiation Oncology Physics: A Handbook for Teachers and Students
55.How do independent audits strengthen dosimetric assurance?
Independent dosimetric audits compare local practice with an external measurement or assessment pathway, helping detect errors shared by a department’s internal checks. Independence matters because repeated calculations using the same assumptions or calibration chain may reproduce the same mistake. Audits complement commissioning and routine quality assurance rather than replacing them. A satisfactory audit supports the specific tested conditions; it does not prove that every plan, workflow or uncommon clinical geometry is correct.
Apply it
All local output checks agree, but they depend on the same calibration pathway. Arrange an independent dosimetric audit to challenge shared assumptions and investigate any discrepancy before concluding that agreement among internal checks establishes absolute dose accuracy.
Common pitfall: Two calculations are not meaningfully independent if they share the same erroneous input or model. Audit scope must also be considered before generalizing its reassurance.
Radiation Protection in Medicine: Setting the Scene for the Next Decade
56.Why should near misses be investigated?
A near miss reveals a failure pathway that could have reached a patient but was intercepted. Studying it can identify weak interfaces, ambiguous responsibilities and defenses that depend too heavily on individual vigilance. Useful analysis examines how the system produced the opportunity for error and how barriers performed. Counting only harmful incidents discards early warning information, while a purely punitive response can reduce reporting and leave the underlying process unchanged.
Apply it
A therapist catches an incorrect plan selection immediately before treatment. Record the near miss, map how the wrong selection became possible and strengthen the workflow so that prevention does not depend solely on another attentive individual noticing it.
Common pitfall: No delivered harm does not mean no safety problem. Blaming the last person in the chain can obscure upstream design flaws and discourage future reporting.
Radiation Protection in Medicine: Setting the Scene for the Next Decade
57.How does prospective risk analysis prevent treatment errors?
Prospective risk analysis examines a workflow before harm occurs, identifying possible failures, their consequences and the likelihood that existing controls would detect them. It is particularly valuable when introducing new technology or transferring information between systems. The process directs attention toward high-consequence, poorly detected failure modes rather than relying only on past incident counts. Its value comes from implementing and reviewing practical safeguards, not merely assigning numerical scores to an unchanged process.
Apply it
Before introducing an automated planning-to-delivery transfer, map each handoff and identify failures such as mismatched identifiers or altered parameters. Add targeted verification and test the safeguards before clinical release, especially where an error could propagate silently.
Common pitfall: Automation can propagate an error consistently and quickly. A low historical incident count does not establish safety for a newly introduced or substantially changed workflow.
Radiation Protection in Medicine: Setting the Scene for the Next Decade
Othernot stated
58.How should similar outcomes in a trial be interpreted?
Clinical evidence must be interpreted by population, intervention, comparator and endpoint. Similar pain relief does not establish equal retreatment rates, and similar local control does not establish identical toxicity. Failure to demonstrate a difference is also not automatically proof of equivalence. Equivalence requires an appropriate study design and a prespecified acceptable difference; a nonsignificant superiority test alone cannot provide that conclusion.
Apply it
A presentation calls single-fraction and longer-course bone irradiation identical. Separate initial pain response from retreatment, check that the patient resembles the studied population and rewrite the conclusion to reflect the specific outcomes actually compared in the trial.
Common pitfall: A single favorable endpoint cannot stand in for the entire benefit–harm profile. Statistical nonsignificance alone does not establish that two interventions are clinically equivalent.
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases · Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial
59.What should informed treatment discussions make clear?
An informed radiation-treatment discussion should connect the treatment purpose with expected benefits, important harms, reasonable alternatives and the consequences of declining treatment. Technical descriptions alone do not show that the patient understands the decision. Explaining intent is especially important when radiotherapy is palliative rather than curative. Discuss the expected symptom benefit separately from control of the treated lesion and control of cancer elsewhere.
Apply it
A patient with painful metastatic disease believes a short radiation course will cure all cancer. Clarify the intended pain-control benefit, possible adverse effects and alternatives, then ask the patient to explain the goal back in their own words.
Common pitfall: A signed form does not establish understanding. Avoid describing palliative treatment in terms that allow the patient to infer an unsupported promise of cure.
Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards, GSR Part 3 · External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline
60.How should patient preferences influence an evidence-supported choice?
When multiple supported treatments offer different trade-offs, patient preferences help determine which option best fits the person’s goals. The clinician should first establish the eligible options and explain differences in disease control, toxicity, monitoring and practical burden. Preference-sensitive choice does not mean offering an unsuitable treatment as equivalent. Life expectancy and competing illness also affect whether a delayed disease-control benefit is likely to outweigh immediate treatment harms.
Apply it
A patient with favorable localized prostate cancer prioritizes avoiding urinary and sexual harm but is anxious about monitoring. Compare surveillance and definitive options using his risk profile, then explore how each option aligns with his priorities and tolerance of uncertainty.
Common pitfall: Preferences should inform a clinically accurate discussion, not replace it. Convenience or anxiety alone cannot make an unsupported or unsuitable treatment equivalent to an indicated option.
Prostate Cancer Treatment (PDQ®)—Health Professional Version
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Explain treatment intent and identify the clinical cue that changes modality selection: operability, disease risk, tumor location, neurological compromise or mechanical instability.
- Distinguish breast irradiation, tumor-bed boost, regional nodal treatment and postmastectomy treatment by the residual disease risk each addresses.
- Keep cervical brachytherapy, concurrent radiosensitization and applicator geometry connected to adequate local treatment.
- Use named risk frameworks to distinguish prostate implant monotherapy, combined treatment and ADT duration; distinguish usual anal radiosensitizing chemotherapy from conditional alternatives.
- Recognize acute pelvic bowel toxicity, investigate severe or persistent symptoms and distinguish late injury from recurrent disease and other diagnoses.
- Separate gross disease, microscopic-risk volumes, internal motion and setup uncertainty before evaluating coverage.
- Calculate inverse-square ratios, BED and EQD2 with explicit assumptions, units and biological endpoints.
- Interpret clinical endpoints separately: local control, survival, pain response, retreatment and toxicity are not interchangeable.
- Practise safety reasoning across justification, optimization, commissioning, independent verification, near misses and prospective workflow analysis.
- Use the official March 2025 revised curriculum to identify additional required subjects beyond this selective guide; no published numerical weights support narrowing preparation to these topics.
A practical preparation plan
1. Map the governing scope
Start with the 2026 notice and its March 2025 revised curriculum basis. Organize your complete preparation under the three official domains, and add required curriculum subjects beyond these 60 selected concepts.
2. Build clinical decision pairs
Compare operable versus inoperable early lung cancer, concurrent versus sequential thoracic treatment, prostate surveillance versus definitive therapy, and uncomplicated bone pain versus instability or cord compression. State the finding that changes the decision.
3. Draw targets before reviewing dose
For representative cases, identify gross disease, microscopic-risk tissue, motion and setup uncertainty. Then inspect spatial dose and dose-volume metrics together, explaining any justified coverage–organ trade-off.
4. Work calculations with assumptions
Practise inverse-square, BED and EQD2 exercises by writing the formula, substituting values and checking direction and units. Name omitted effects such as repopulation, incomplete repair or tissue heterogeneity.
5. Rehearse concise oral explanations
Present each case as indication, decisive findings, preferred strategy, reasonable alternatives and major safety checks. Include immediate emergency actions and toxicity findings that require investigation. Practise explaining judgment without assuming an unverified oral station format.
6. Use errors to direct revision
Complete the independent questions, explain why every alternative is less appropriate, and revisit the underlying concepts. Review flashcards with brief reasoning, then test the same principle in a different clinical or physics scenario.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- 第３回日本専門医機構認定放射線治療専門医認定試験について
- 放射線治療専門医制度
- 令和8年度専門医試験結果
- Breast Cancer Treatment (PDQ®)—Health Professional Version
- Non-Small Cell Lung Cancer Treatment (PDQ®)—Health Professional Version
- Cervical Cancer Treatment (PDQ®)—Health Professional Version
- Prostate Cancer Treatment (PDQ®)—Health Professional Version
- Anal Cancer Treatment (PDQ®)—Health Professional Version
- External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline
- Radiation Oncology Physics: A Handbook for Teachers and Students
- Radiation Biology: A Handbook for Teachers and Students
- Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards, GSR Part 3
- Radiation Protection in Medicine: Setting the Scene for the Next Decade
- 日本専門医機構について
- Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases
- Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial
- Pub1578_web-57265295.pdf
- Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 - PMC
- STPC%20Unabridged%20Final.pdf
- Recommendations | Spinal metastases and metastatic spinal cord compression | Guidance | NICE
- Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410 - PMC
- Gastrointestinal Complications (PDQ®) - NCI
- Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial - PMC
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.